PR Newswire Clinical TrialsOriginal article
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
Data ReadoutpositiveSurabgene LomparvovecPositive
AI Analysis
Summary
REGENXBIO announced positive long-term data for surabgene lomparvovec showing stable to improved vision through 5 years in wet AMD patients at the American Society of Retina Specialists Annual Meeting. The one-time gene therapy treatment demonstrated efficacy at doses being evaluated in ongoing late-stage studies.
Clinical Trial Data
Phase
late-stage
Primary Endpoint
Met
Outcome Details
Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec treatment
Importance:7/10
Sentiment:
0.80
gene therapyophthalmologywet AMDdiabetic retinopathylong-term datalate-stage development
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 18, 2026 6:55 PM